Neuregulin 1-induced AKT and ERK phosphorylation in patients with Fragile X Syndrome (FXS) and intellectual disability associated with obstetric complications

Journal of Molecular Neuroscience

Volumn 54, Issue 1, 2014, Pages 119-124

  Kovács, Tamás ^a   Bánsági, Boglárka ^b   Kelemen, Oguz ^c   Kéri, Szabolcs ^a,d,e  

^a NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

^d UNIVERSITY OF SZEGED   (Hungary)

^e BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

AKT; ERK; Fragile X syndrome; Neuregulin 1

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B;

ARTICLE; B LYMPHOBLAST; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FETUS HYPOXIA; FRAGILE X SYNDROME; HUMAN; INTELLECTUAL IMPAIRMENT; LOW BIRTH WEIGHT; MALE; PERIPHERAL LYMPHOCYTE; PREMATURE LABOR; ADULT; B LYMPHOCYTE; CASE CONTROL STUDY; GENETICS; INTELLECTUAL DISABILITY; LABOR COMPLICATION; METABOLISM; PHOSPHORYLATION; PREGNANCY; SIGNAL TRANSDUCTION;

ANIMALIA;

ADULT; B-LYMPHOCYTES; CASE-CONTROL STUDIES; FEMALE; FRAGILE X SYNDROME; HUMANS; INTELLECTUAL DISABILITY; MALE; MAP KINASE SIGNALING SYSTEM; NEUREGULIN-1; OBSTETRIC LABOR COMPLICATIONS; PHOSPHORYLATION; PREGNANCY; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84906349038     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0257-z     Document Type: Article

References (50)

1. American Association on Intellectual and Developmental Disabilities (2010) Intellectual disability: definition, classification, and systems of supports. 11th Edition. Washington, DC
2. Backx L, Ceulemans B, Vermeesch JR, Devriendt K, Van Esch H (2009) Early myoclonic encephalopathy caused by a disruption of the neuregulin-1 receptor ErbB4. Eur J Hum Genet 17:378-382
3. Britsch S (2007) The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 190:1-65
4. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST (2001) Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477-487 (Pubitemid 33152783)
5. Centonze D, Rossi S, Mercaldo V, Napoli I, Ciotti MT, De Chiara V, Musella A, Prosperetti C, Calabresi P, Bernardi G, Bagni C (2008) Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry 63:963-973 (Pubitemid 351602272)
6. Cleva RM, Olive MF (2011) Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules 16:2097-2106
7. De Rubeis S, Bagni C (2011) Regulation of molecular pathways in the fragile x syndrome: insights into autism spectrum disorders. J Neurodev Disord 3:257-269
8. Fatemi SH, Folsom TD (2011) The role of fragile X mental retardation protein in major mental disorders. Neuropharmacology 60:1221-1226
9. Fatemi SH, Kneeland RE, Liesch SB, Folsom TD (2010) Fragile X mental retardation protein levels are decreased in major psychiatric disorders. Schizophr Res 124:246-247
10. Fatemi SH, Folsom TD, Rooney RJ, Thuras PD (2013) mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry 3:e271
11. Fazzari P, Paternain AV, Valiente M, Pla R, Luján R, Lloyd K, Lerma J, Marín O, Rico B (2010) Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature 464:1376-1380
12. Fisch GS, Carpenter N, Howard-Peebles PN, Maddalena A, Simensen R, Tarleton J, Julien-Inalsingh C, Chalifoux M, Holden JJ (1996) Lack of association between mutation size and cognitive/behavior deficits in fragile X males: a brief report. Am J Med Genet 64:362-364
13. Ghosh A, Michalon A, Lindemann L, Fontoura P, Santarelli L (2013) Drug discovery for autism spectrum disorder: challenges and opportunities. Nat Rev Drug Discov 12:777-790
14. Hagerman RJ (2011) The fragile X-associated disorders: time to order fragile X DNA testing. Biol Psychiatry 70:802-803
15. Harrison PJ, Law AJ (2006) Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60:132-140
16. Hessl D, Wang JM, Schneider A, Koldewyn K, Le L, Iwahashi C, Cheung K, Tassone F, Hagerman PJ, Rivera SM (2011) Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biol Psychiatry 70:859-865
17. Hoeffer CA, Sanchez E, Hagerman RJ, Mu Y, Nguyen DV, Wong H, Whelan AM, Zukin RS, Klann E, Tassone F (2012) Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav 11:332-334
18. Hong A, Zhang A, Ke Y, El Idrissi A, Shen CH (2012) Downregulation of GABA(A) β subunits is transcriptionally controlled by Fmr1p. J Mol Neurosci 46:272-275
19. Hou L, Klann E (2004) Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci 24:6352-6361 (Pubitemid 38944226)
20. Hu H, Qin Y, Bochorishvili G, Zhu Y, van Aelst L, Zhu JJ (2008) Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J Neurosci 28:7847-7862
21. Jaaro-Peled H, Hayashi-Takagi A, Seshadri S, Kamiya A, Brandon NJ, Sawa A (2009) Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci 32:485-495
22. Jeon SJ, Seo JE, Yang SI, Choi JW, Wells D, Shin CY, Ko KH (2011) Cellular stress-induced up-regulation of FMRP promotes cell survival by modulating PI3K-Akt phosphorylation cascades. J Biomed Sci 13:17
23. Jeon SJ, Han SH, Yang SI, Choi JW, Kwon KJ, Park SH, Kim HY, Cheong JH, Ryu JH, Ko KH, Wells DG, Shin CY (2012) Positive feedback regulation of Akt-FMRP pathway protects neurons from cell death. J Neurochem 123:226-238
24. Kanakry CG, Li Z, Nakai Y, Sei Y, Weinberger DR (2007) Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer. PLoS One 2:e1369
25. Kelemen O, Kovács T, Kéri S (2013) Contrast, motion, perceptual integration, and neurocognition in schizophrenia: the role of fragile-X related mechanisms. Prog Neuropsychopharmacol Biol Psychiatry 46:92-97
26. Kéri S, Seres I, Kelemen O, Benedek G (2009) Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. Neurochem Int 55:606-609
27. Kéri S, Beniczky S, Kelemen O (2010) Suppression of the P50 evoked response and neuregulin 1-induced AKT phosphorylation in first-episode schizophrenia. Am J Psychiatry 167:444-450
28. Kéri S, Seres I, Kelemen O, Benedek G (2011) The relationship among neuregulin 1-stimulated phosphorylation of AKT, psychosis proneness, and habituation of arousal in nonclinical individuals. Schizophr Bull 37:141-147
29. Kovács T, Kelemen O, Kéri S (2013) Decreased fragile X mental retardation protein (FMRP) is associated with lower IQ and earlier illness onset in patients with schizophrenia. Psychiatry Res 30:690-693
30. Krueger DD, BearMF (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62:411-429
31. Kurnianingsih YA, Kuswanto CN, McIntyre RS, Qiu A, Ho BC, Sim K (2011) Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. J Neural Transm 118:1621-1639
32. Li R, Shen Y (2013) An old method facing a new challenge: re-visiting housekeeping proteins as internal reference control for neuroscience research. Life Sci 92:747-751
33. Loat CS, Craig G, Plomin R, Craig IW (2006) Investigating the relationship between FMR1 allele length and cognitive ability in children: a subtle effect of the normal allele range on the normal ability range? Ann Hum Genet 70:555-565 (Pubitemid 44173367)
34. Lugo JN, Smith GD, Morrison JB, White J (2013) Deletion of PTEN produces deficits in conditioned fear and increases fragile X mental retardation protein. Learn Mem 20:670-673
35. Macpherson J, Sawyer H (2005) Practice guidelines for molecular diagnosis of fragile X syndrome. Clinical Molecular Genetics Society, UK, http://www.cmgs.org/
36. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH (2010) Consensus statement: chromosomalmicroarray is a firsttier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 86:749-764
37. O'Donnell WT, Warren ST (2002) A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 25:315-338 (Pubitemid 34748020)
38. Paluszkiewicz SM, Martin BS, Huntsman MM (2011) Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci 33:349-364
39. Reiss AL, Hall SS (2007) Fragile X syndrome: assessment and treatment implications. Child Adolesc Psychiatr Clin N Am 16:663-675 (Pubitemid 46880399)
40. Rousseau F, Labelle Y, Bussières J, Lindsay C (2011) The fragile X mental retardation syndrome 20 years after the FMR1 gene discovery: an expanding universe of knowledge. Clin Biochem Rev 32:135-162
41. Rustan OG, Folsom TD, YousefiMK, Fatemi SH (2013) Phosphorylated fragile X mental retardation protein at serine 499, is reduced in cerebellar vermis and superior frontal cortex of subjects with autism: implications for fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling. Mol Autism 4:41
42. Sei Y, Ren-Patterson R, Li Z, Tunbridge EM, Egan MF, Kolachana BS, Weinberger DR (2007)Neuregulin1-induced cellmigration is impaired in schizophrenia: association with neuregulin1 and catechol-omethyltransferase gene polymorphisms. Mol Psychiatry 12:946-957 (Pubitemid 47482694)
43. Sei Y, Li Z, Song J, Ren-Patterson R, Tunbridge EM, Iizuka Y, Inoue M, Alfonso BT, Beltaifa S, Nakai Y, Kolachana BS, Chen J, Weinberger DR (2010) Epistatic and functional interactions of catechol-omethyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models. PLoS One 5:e10789
44. Seres I, Kelemen O, Benedek G, Kéri S (2010) Neuregulin 1-induced AKT phosphorylation in monozygotic twins discordant for schizophrenia. Neurochem Int 56:906-910
45. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, Zukin R (2010) Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 30:694-702
46. Sokol DK, Maloney B, Long JM, Ray B, Lahiri DK (2011) Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 76:1344-1352
47. Ting AK, Chen Y, Wen L, Yin DM, Shen C, Tao Y, Liu X, Xiong WC, Mei L (2011) Neuregulin 1 promotes excitatory synapse development and function in GABAergic interneurons. J Neurosci 31:15-25
48. Wechsler D (1997) The Wechsler Adult Intelligence Scale-III: administration and scoring manual. The Psychological Corporation, San Antonio
49. Willemsen R, Levenga J, Oostra BA (2011) CGG repeat in the FMR1 gene: size matters. Clin Genet 80:214-225
50. Zeng L, Guo J, Xu HB, Huang R, ShaoW, Yang L, Wang M, Chen J, Xie P (2013) Direct Blue 71 staining as a destaining-free alternative loading control method for Western blotting. Electrophoresis 34:2234-2239